Patient demographics
| Characteristics . | No. . |
|---|---|
| Total number of patients | 52 |
| KPS, range (median) | 70-100 (90) |
| M:F | 30:22 |
| Age, range (median) y | 19.5-62 (47.3) |
| Diseases | |
| AML CR1 | 9 |
| Intermediate* | 6 |
| High risk* | 3 |
| AML CR2 | 7 |
| AML CR1 after MDS | 5 |
| ALL CR1 | 5 |
| Ph+ | 3 |
| Ph+, mono 7 | 1 |
| t(9;17), mono 7 | 1 |
| ALL CR2 | 1 |
| ALL CR3 or greater | 1 |
| AL, other | 3 |
| CML CP1 | 4 |
| CML, advanced | 2 |
| MDS | 2 |
| RA after AML | 1 |
| RAEB-IT | 1 |
| NHL | 11 |
| B cell | |
| Low | 1 |
| Intermediate | 5 |
| High | 4 |
| T cell | 1 |
| T-PLL | 2 |
| Donors | |
| M → F | 11 |
| M → M | 16 |
| F → M | 14 |
| F → F | 11 |
| Age, range (median), y | 14-71 (45) |
| Grafts | |
| PBSC | 47 |
| BM | 4 |
| Both | 1 |
| Characteristics . | No. . |
|---|---|
| Total number of patients | 52 |
| KPS, range (median) | 70-100 (90) |
| M:F | 30:22 |
| Age, range (median) y | 19.5-62 (47.3) |
| Diseases | |
| AML CR1 | 9 |
| Intermediate* | 6 |
| High risk* | 3 |
| AML CR2 | 7 |
| AML CR1 after MDS | 5 |
| ALL CR1 | 5 |
| Ph+ | 3 |
| Ph+, mono 7 | 1 |
| t(9;17), mono 7 | 1 |
| ALL CR2 | 1 |
| ALL CR3 or greater | 1 |
| AL, other | 3 |
| CML CP1 | 4 |
| CML, advanced | 2 |
| MDS | 2 |
| RA after AML | 1 |
| RAEB-IT | 1 |
| NHL | 11 |
| B cell | |
| Low | 1 |
| Intermediate | 5 |
| High | 4 |
| T cell | 1 |
| T-PLL | 2 |
| Donors | |
| M → F | 11 |
| M → M | 16 |
| F → M | 14 |
| F → F | 11 |
| Age, range (median), y | 14-71 (45) |
| Grafts | |
| PBSC | 47 |
| BM | 4 |
| Both | 1 |
CR indicates complete remission; AL, acute leukemia multilineage; CML, chronic myelogenous leukemia; CP, chronic phase; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB-IT, refractory anemia with excess blasts in transformation; and T-PLL, T-cell prolymphocytic leukemia.
By cytogenetics.